<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00584090</url>
  </required_header>
  <id_info>
    <org_study_id>4</org_study_id>
    <secondary_id>104803b</secondary_id>
    <nct_id>NCT00584090</nct_id>
  </id_info>
  <brief_title>Solifenacin Succinate (VESIcare) for the Treatment of Urinary Incontinence in Parkinson's Disease</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of South Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of South Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to measure the efficacy of solifenacin succinate&#xD;
      (VESIcare) on treating urinary incontinence in Parkinson's disease patients.&#xD;
&#xD;
      The secondary objective of this study is to examine the effect of solifenacin succinate&#xD;
      (VESIcare) on symptoms of PD and the patient's quality of life.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study withdrawn with intent of persuing larger, multi-site study.&#xD;
  </why_stopped>
  <start_date>November 2007</start_date>
  <primary_completion_date type="Anticipated">April 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary purpose of this study is to measure the efficacy of solifenacin succinate (VESIcare) on treating urinary incontinence in Parkinson's disease patients.</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary objective of this study is to examine the effect of solifenacin succinate (VESIcare) on symptoms of PD and the patient's quality of life.</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Urinary Incontinence</condition>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin Succinate (VESIcare)</intervention_name>
    <description>5 - 10 mg po qd for 1 month</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo equivalent of 5-10 mg po qd for 1 month</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Outpatients with idiopathic PD according to the UK Parkinson's Disease Society Brain&#xD;
             Bank Clinical Diagnosis Criteria.&#xD;
&#xD;
          2. Age 30 years to 80 years.&#xD;
&#xD;
          3. Stable dose of antiparkinsonian medication 4 weeks prior to study entry.&#xD;
&#xD;
          4. Patients must score 18 or higher on the UPDRS scale and 1.0 to 2.5 on the Modified&#xD;
             Hoehn and Yahr scale.&#xD;
&#xD;
          5. Women of child-bearing potential must use a reliable method of contraception.&#xD;
&#xD;
          6. Must be experiencing symptoms of urinary incontinence (voiding 8 or more times/day or&#xD;
             episodes of incontinence 5 or more times per week).&#xD;
&#xD;
          7. Patients must have evidence of normal PSA and urodynamic tests within the last 12&#xD;
             months.&#xD;
&#xD;
          8. Clearance from the patient's urologist or internist who has examined the patient&#xD;
             within the last 12-months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any illness that in the investigator's opinion preclude participation in this study.&#xD;
&#xD;
          2. Pregnancy or lactation.&#xD;
&#xD;
          3. Concurrent participation in another clinical study.&#xD;
&#xD;
          4. Dementia or other psychiatric illness that prevents the patient from giving informed&#xD;
             consent (Mini Mental Status Exam score less than 24).&#xD;
&#xD;
          5. Legal incapacity or limited legal capacity.&#xD;
&#xD;
          6. Presence of severe renal disease (BUN 50% greater than normal).&#xD;
&#xD;
          7. Presence of major hepatic impairment.&#xD;
&#xD;
          8. Currently taking ketaconazole (anti-fungal) or any CYP3A4 inhibitor.&#xD;
&#xD;
          9. Any history of bladder outflow obstruction or gastrointestinal obstructive disorders.&#xD;
&#xD;
         10. History of controlled narrow angle glaucoma.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theresa A Zesiewicz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2010</verification_date>
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2008</study_first_posted>
  <last_update_submitted>November 30, 2012</last_update_submitted>
  <last_update_submitted_qc>November 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2012</last_update_posted>
  <responsible_party>
    <name_title>Theresa Zesiewicz, MD</name_title>
    <organization>University of South Florida</organization>
  </responsible_party>
  <keyword>urinary incontinence</keyword>
  <keyword>parkinson's disease</keyword>
  <keyword>vesicare</keyword>
  <keyword>solifenacin succinate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solifenacin Succinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

